Physician profile
Amanda E Magnoli
NPI 1689945420
$113,268.25
in general payments reported to CMS, 2019-2025
25 companies · $50K in 2025
The $50K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.42 · 2022: $410 · 2023: $21K · 2024: $42K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Travel and Lodging: $25K · Food and Beverage: $5,714 · Consulting Fee: $1,835 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,187.50 |
| Travel and Lodging | $24,899.79 |
| Food and Beverage | $5,714.03 |
| Consulting Fee | $1,835.00 |
| Education | $172.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $42,548.62 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Astrazeneca Pharmaceuticals Lp | $38,741.09 | 2023-2025 | Enhertu, Datroway, Tagrisso |
| Gilead Sciences, INC. | $30,588.50 | 2023-2025 | Trodelvy |
| Abbvie INC. | $195.81 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.31 | 2023-2024 | Ninlaro, Alunbrig |
| Incyte Corporation | $127.72 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| Glaxosmithkline, LLC. | $117.90 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $104.21 | 2021-2023 | Imbruvica |
| Tempus Ai, INC | $84.49 | 2024 | |
| Rigel Pharmaceuticals, INC. | $83.63 | 2022 | |
| Genzyme Corporation | $72.34 | 2023-2025 | |
| Janssen Biotech, INC. | $72.19 | 2022-2024 | Rybrevant |
| Amgen INC. | $61.04 | 2023 | Lumakras, Kyprolis, Vectibix |
| Novocure INC. | $40.55 | 2025 | Optune Lua (Novottf-200t) |
| Blueprint Medicines Corporation | $39.67 | 2023 | Ayvakit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $35.11 | 2025 | |
| Novartis Pharmaceuticals Corporation | $29.76 | 2025 | |
| Aimmune Therapeutics, INC. | $29.10 | 2025 | Vowst |
| Regeneron Healthcare Solutions, INC. | $23.36 | 2025 | Libtayo |
| Puma Biotechnology, INC. | $22.19 | 2025 | |
| Tolmar, INC. | $18.18 | 2025 | |
| Eisai INC. | $18.04 | 2025 | |
| Stemline Therapeutics INC. | $16.73 | 2025 | Orserdu |
| Merck Sharp & Dohme LLC | $15.04 | 2025 | Keytruda, Welireg, Lynparza |
| Caris Mpi, INC. | $13.67 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Magnoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.